Generex inks deal with Sanofi-Aventis for insulin supply
The API (Active Pharmaceutical Ingredient) Supply agreement will provide the Company with a source of insulin for major regulatory markets including the United States and Canada and a number of other regions where the Company is pursuing regulatory approvals for Generex Oral-lyn™. The Company’s regulatory team will commence the process of updating any and all current submissions to include sanofi-aventis’ insulin crystal which will be formulated in the Generex Oral-lyn™ commercial product.
“We are very pleased to have entered into this long term supply agreement for insulin crystal”, said Anna Gluskin, Generex’s President and Chief Executive Officer. “It solidifies one of our key product components which will assist in the smooth transition into commercialization of our flagship product, Generex Oral-lyn™, into major markets where we will seek to establish a new paradigm for the treatment of diabetes.”
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.